01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
07:00 , Mar 19, 2015 |  BC Innovations  |  Product R&D

AAV for HIV

On top of the problem of creating an HIV vaccine against a rapidly mutating virus, immunologists have been stumped for many years by the fact that preventing access to CD4 - HIV's key entry point...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Not applicable In vitro studies suggest inducing an IgG3 response against HIV antigens could help...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

ALVAC HIV vaccine: Additional Phase III data

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine missed...
07:00 , Oct 26, 2009 |  BioCentury  |  Product Development

Correlates and Endpoints

Details matter. While the first reports on a combination HIV vaccine suggested proof that both a T cell and an antibody response are needed to provide protection, the complete data disclosed last week are far...
07:00 , Oct 26, 2009 |  BioCentury  |  Finance

Ebb & Flow

Despite the brutal fundraising environment, New Enterprise Associates is close to wrapping up its 13th fund. According to an SEC filing, the firm has raised $2.46 billion of a planned $2.5 billion, which would put...
00:45 , Oct 21, 2009 |  BC Extra  |  Clinical News

Detailed data from HIV vaccine trial released

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by the AIDSVAX B/E gp120 vaccine...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

ALVAC HIV vaccine: Phase III data

Data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine lowered the rate...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
00:40 , Sep 25, 2009 |  BC Extra  |  Clinical News

Vaccine combination lowers rate of HIV infection

The U.S. Army Surgeon General released data from the Phase III RV144 trial showing that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by the AIDSVAX B/E gp120 vaccine lowered the rate of HIV...